BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Week in Review: Hisun-Pfizer Inc. (PFE) and Merck & Co., Inc. (MRK)-Simcere Pharmaceutical Group JVs Come Into Focus


5/28/2013 9:32:15 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

May 25, 2013 -- Zhejiang Hisun Pharma contributed 75 drug products to gain 51% control of its JV with Pfizer, while Pfizer added eight drugs; the Merck-Simcere JV is focused onsix cardiovascular drugs, two from Simcere and the rest from Merck; 3SBio’s shareholders voted to accept a go-private offer priced at $16.70 per ADS; Janssen Pharma, a division of Johnson & Johnson, has four new medical entities awaiting approval in China and expects to file an additional nine NMEs by 2017; GlaxoSmithKline cut the prices of its China drugs and watched revenues jump as a result; Zensun Sci & Tech, a Shanghai-San Diego biopharma, reported positive results from four Phase II trials of its heart failure drug, Neucardin™; the CFDA approved clinical trials of a novel AIDS treatment developed at Zhengzhou University; Curative Medical will oversee a China clinical trial for ALung’s respiratory medical device; and China’s bird flu crisis has been contained, according to UN officials. More details….

Stock Symbols: (SHA: 600267) (NYSE: PFE) (NYSE: MRK) (NYSE: SCR) (NSDQ: SSRX) (NYSE: JNJ) (NYSE: GSK)



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES